期刊
EMBO MOLECULAR MEDICINE
卷 5, 期 4, 页码 572-590出版社
WILEY
DOI: 10.1002/emmm.201201876
关键词
complement C3; experimental autoimmune myocarditis; interleukin-6; immune-mediated myocarditis; STAT3
资金
- Regione Piemonte
- Italian Ministry for University and Research (FIRB)
- Italian Ministry for University and Research (MIUR)
- Italian Ministry of Health
- Italian Association for Cancer Research (AIRC)
- Alberta Innovates [201201230] Funding Source: researchfish
Myocarditis, often triggered by viral infection, may lead to heart auto-immunity and dilated cardiomyopathy. What determines the switch between disease resolution and progression is however incompletely understood. We show that pharmacological inhibition of STAT3, the main mediator of IL-6 signalling and of Th17-cell differentiation, protects mice from the development of Experimental Auto-immune Myocarditis reducing liver production of the complement component C3, and can act therapeutically when administered at disease peak. Further, we demonstrate that STAT3 is sufficient when constitutively active for triggering the onset of immune-mediated myocarditis, involving enhanced complement C3 production and IL-6 signalling amplification in the liver. Disease development can be prevented by C3 depletion and IL-6 receptor neutralization. This appears to be relevant to disease pathogenesis in humans, since acute myocarditis patients display significantly elevated circulating IL-6 and C3 levels and activated heart STAT3. Thus, aberrant IL-6/STAT3-mediated induction of liver acute phase response genes including C3, which occurs as a consequence of pre-existing inflammatory conditions, might represent an important factor determining the degree of myocarditis and its clinical outcome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据